- Home
- VMD vs DMAC Comparison
VMD vs DMAC Comparison
Compare VMD & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMD
- DMAC
- Stock Information
- Founded
- VMD 2006
- DMAC 2000
- Country
- VMD United States
- DMAC United States
- Employees
- VMD N/A
- DMAC N/A
- Industry
- VMD
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- VMD
- DMAC Health Care
- Exchange
- VMD Nasdaq
- DMAC Nasdaq
- Market Cap
- VMD 273.5M
- DMAC 178.0M
- IPO Year
- VMD N/A
- DMAC N/A
- Fundamental
- Price
- VMD $6.74
- DMAC $3.63
- Analyst Decision
- VMD
- DMAC Strong Buy
- Analyst Count
- VMD 0
- DMAC 2
- Target Price
- VMD N/A
- DMAC $8.00
- AVG Volume (30 Days)
- VMD 201.5K
- DMAC 326.6K
- Earning Date
- VMD 08-06-2025
- DMAC 08-06-2025
- Dividend Yield
- VMD N/A
- DMAC N/A
- EPS Growth
- VMD 19.95
- DMAC N/A
- EPS
- VMD 0.30
- DMAC N/A
- Revenue
- VMD $232,793,000.00
- DMAC N/A
- Revenue This Year
- VMD $17.35
- DMAC N/A
- Revenue Next Year
- VMD $12.87
- DMAC N/A
- P/E Ratio
- VMD $22.50
- DMAC N/A
- Revenue Growth
- VMD 19.97
- DMAC N/A
- 52 Week Low
- VMD $6.14
- DMAC $3.00
- 52 Week High
- VMD $9.81
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- VMD 45.43
- DMAC 44.55
- Support Level
- VMD $6.86
- DMAC $3.48
- Resistance Level
- VMD $7.07
- DMAC $3.88
- Average True Range (ATR)
- VMD 0.22
- DMAC 0.26
- MACD
- VMD -0.01
- DMAC 0.00
- Stochastic Oscillator
- VMD 27.14
- DMAC 30.10
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.